Lectures

• 

  1. Cancer: From Mystery to Industry

  In our introductory lecture, Gerald Posner explores the evolution of cancer from an ancient, mysterious disease to a modern industrial empire, examining how financial and political influences have shaped the field to prioritize treatment over prevention. We trace the journey from early misconceptions about cancer's causes through pioneering discoveries in surgery and radiation by figures like Halsted, Röntgen, and the Curies, to the establishment of federal funding. The lecture concludes by highlighting how profit-driven treatment has overshadowed prevention efforts, despite many core treatment methods remaining largely unchanged for nearly a century.
• 

  2. Origins of Chemotherapy

  In lecture two, we learn about the origins of chemotherapy, tracing its development from World War II-era chemical warfare research to its role as a cornerstone of cancer treatment. We examine figures like Cornelius Rhoads, Sidney Farber, and Mary Lasker, who helped transform chemotherapy into an established medical approach despite its severe toxicity and limited early benefits. Posner concludes by showing how federal funding, research centers, pharmaceutical interests, and philanthropy created a powerful “cancer treatment machine” focused on chemotherapy while largely sidelining prevention, a pattern that continues in modern oncology.
• 

  3. Who Controls Treatment?

  In lecture three, we turn to the historical and political dynamics of the cancer care industry, focusing on how the American Medical Association and cancer establishment used gatekeeping mechanisms and the label “quackery” to control which treatments gained legitimacy. Through case studies, we explore how institutional responses followed a consistent template: attacking credibility, cutting off research funding, and blocking sales, often without conducting rigorous independent testing to determine whether alternative treatments had merit. Posner emphasizes the need to protect patients from genuine charlatans while ensuring promising alternatives receive fair scientific evaluation.
• 

  4. The War on Cancer

  In lecture four, we examine the political and institutional evolution of President Nixon’s “war on cancer” and how it transformed cancer research and treatment into a massive federal enterprise. We trace the development of comprehensive cancer centers, the expansion of National Cancer Institute funding from $223 million to over $7 billion, and the continued emphasis on treatment over prevention. Posner critically analyzes how the war metaphor reshaped priorities by creating expectations of victory, marginalizing research on environmental and occupational carcinogens, and producing a treatment-focused system that has not significantly reduced mortality relative to its enormous investment.
• 

  5. Carcinogen Cover-Ups

  In lecture five, we analyze corporate cover-ups and regulatory failures surrounding cancer-causing substances through three case studies: saccharin, vinyl chloride, and asbestos. We explore how industries suppressed evidence, manipulated scientific findings, and delayed regulation while workers and consumers remained exposed to known carcinogens. The lecture concludes by highlighting how journalists and activists like Samuel Epstein and Rachel Carson exposed these practices, shifting public perceptions of government and industry claims about cancer.
• 

  6. Breast Cancer & Branding

  In lecture six, we trace breast cancer’s transformation from a stigmatized disease into a powerful global marketing platform symbolized by the pink ribbon. We examine how grassroots advocacy by survivors and public figures like Betty Ford and Nancy Brinker grew into influential nonprofits that secured research funding and changed the patient-doctor dynamic. We also explore advances in surgical techniques and controversies surrounding the breast cancer brand, including corporate “pinkwashing” and underexplored environmental, lifestyle and reproductive factors, and occupational risk factors. Ultimately, Posner emphasizes informed consent and patient empowerment, arguing that individuals deserve to make their own healthcare decisions.
• 

  7. Biotechnology Breakthroughs

  In lecture seven, we explore revolutionary cancer treatments including immunotherapy, CAR T-cell therapy, and CRISPR gene editing, examining their potential alongside challenges such as severe side effects, high costs, and limited accessibility. We also investigate conflicts of interest in cancer research, showing how financial ties between researchers, pharmaceutical companies, and medical journals can undermine trust and scientific integrity. The discussion concludes that while biotechnologies advance at breakneck speed, ethical frameworks and regulatory oversight continue to lag dangerously behind.
• 

  8. Cancer’s New Frontier

  In our eighth and final lecture, we explore the future of cancer care, focusing on emerging technologies like liquid biopsies, multi-cancer early detection, and AI-powered diagnostics that promise earlier detection and personalized treatment. We also discuss ethical concerns surrounding AI, including privacy, bias, and the need for human oversight in medical decision-making. Our course concludes with a call for systemic reform, emphasizing prevention, research transparency, regulatory independence, and patient empowerment in a system that prioritizes institutional and corporate interests over public health.